An independent DSMB found no safety concerns at six months in Annovis Bio’s pivotal Phase 3 Alzheimer’s trial of the oral agent buntanetap and recommended the study continue unchanged. Safety outcomes mirrored those observed at six months in the company’s Parkinson’s program. The Alzheimer’s study is roughly 40% enrolled, with subsequent safety reviews slated at 12 and 18 months. A first symptomatic efficacy readout is targeted for early 2027, followed by a disease-modifying assessment in early 2028.
The core development is operational: the DSMB reviewed unblinded safety data in a closed session and supported continuation without protocol modifications. Annovis also indicated that FDA may consider pooled safety across its Alzheimer’s and Parkinson’s programs in a future NDA, a signal that the agency could accept cross-indication exposure data for tolerability, while maintaining indication-specific efficacy standards. The Alzheimer’s trial (NCT06709014) is recruiting across U.S. sites and remains on the original timeline for interim and long-term outcomes.
Strategically, a clean six-month safety look preserves momentum in a crowded Alzheimer’s landscape where tolerability has become a competitive lever as much as efficacy. For an oral, once-daily small molecule that aims to reduce translation of multiple neurotoxic proteins, the absence of early safety flags supports differentiation from antibody-based approaches that carry imaging and infusion burdens. The potential to pool safety across neurodegenerative indications is both a resource- and time-sparing tactic for a smaller sponsor and a practical way to achieve the patient-exposure thresholds FDA often expects in chronic diseases. The trade-off is the long interval before any efficacy clarity: with symptomatic data not expected until 2027, safety alone does not de-risk the program, and operational execution must sustain through protracted follow-up.
For sites and CROs, the DSMB’s “no changes” decision removes the disruption of mid-trial amendments, retraining, and reconsent, preserving screen-to-randomization flow and avoiding new safety procedures that can depress enrollment. The scheduled 12- and 18-month reviews keep ongoing vigilance in place, elevating the importance of retention tactics, adherence monitoring, and consistent AE capture over an extended timeline. If safety pooling with the Parkinson’s program advances, data management teams will need harmonized coding, aligned MedDRA versions, and consistent causality frameworks to support an integrated safety summary acceptable to regulators. Vendors supporting imaging, ePRO, and remote monitoring should expect continuity rather than scope changes, but the extended follow-up emphasizes the value of low-friction tools that reduce site and patient burden.
For regulators, the prospect of cross-indication safety pooling fits a broader pattern of flexibility on exposure datasets when mechanisms and target populations overlap, without softening efficacy expectations. For competing sponsors, the readout cadence highlights a widening split between fast biomarker-driven surrogates and slower, clinically focused endpoints; operational patience and financing durability become as critical as science.
The next checkpoints are enrollment velocity against plan, the 12- and 18-month DSMB reviews, and clarity on how the symptomatic and disease-modifying endpoints are operationalized alongside any biomarker strategy. Watch for policies on concomitant use or exclusion of anti-amyloid therapies, which can influence both safety signals and generalizability. If pooled safety is ultimately accepted, it could streamline an eventual NDA package, but it will not compress the path to persuasive efficacy. The execution risk remains concentrated in retention through 18 months, competition for Alzheimer’s participants across multiple modalities, and sustaining operational quality until the 2027–2028 efficacy horizon.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
